137 results
Page 5 of 7
8-K
EX-1.1
vjjq0i x9jw82en6zuc
21 Feb 20
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:46pm
424B5
gzka dmqt4lb
21 Feb 20
Prospectus supplement for primary offering
4:26pm
424B5
9xqy4ch89 yfbusa648
20 Feb 20
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
ijc62crianjd
20 Feb 20
Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
4:27pm
8-K
EX-4.1
g4mzvq mvx07n6
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
nzhl9zx32vl4
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-4.2
b7j4swss32ya8li6dje5
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
toyu06 nd03f6x8a
14 Nov 19
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
4:38pm
8-K
EX-1.1
dpabqnj
8 Nov 19
Entry into a Material Definitive Agreement
4:38pm
424B5
t0vdpnx7
8 Nov 19
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
1dte 057vm778s3j
31 Oct 19
Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval
4:30pm
8-K
EX-1.1
fibbfycgv lhkudi3
2 Aug 19
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:50pm
424B5
gu582e1s4exn1
2 Aug 19
Prospectus supplement for primary offering
4:40pm
424B5
c2fi4q7508d 83nk047
1 Aug 19
Prospectus supplement for primary offering
4:21pm